Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Business Insights | The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality being the ideological basis of these welfare states, a significant public commitment exists towards ensuring access to high quality health care for all citizens. Whilst doctors make the choice of the medication, the authorities pay the cost of these drugs, insuring citizens against large drug expenses. The public sector bears this cost of pharmaceuticals either directly through hospitals or by providing reimbursement to patients. Pharmaceutical price regulation comes into play not just at the point of sale to the final consumer but at all parts of the distribution chain. Price regulation also varies depending on whether the drug is a patent protected prescription drug or a prescription drug facing generic competition or a non-prescription drug. The prevalence of parallel trade further shapes the dynamics of the pharmaceutical market in the Scandinavian region, while also affecting the states’ expenditure on health. Incentives existing for patients and pharmacists to switch to a lower priced product drive savings from parallel trade. In Sweden for instance, the state is able to generate significant savings as parallel imports are considered substitutable products under the generic substitution policy and pharmacists are required to always dispense the cheapest of alternative products.

Published: March 2009 - Europe.
Table of Contents
Price: $3,835.00 / €2,565.62

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions